ReShape Lifesciences (RSLS) said Monday that the US Patent and Trademark Office awarded a notice of allowance for its proprietary diabetes neuromodulation technology, under patent application, titled high-frequency low duty cycle patterns for neural regulation.

The neuromodulation technology uses vagus nerve block technology platform, along with vagus nerve stimulation, to treat type 2 diabetes.

The technology regulates blood glucose through targeted vagal nerve modulation, specifically, blocking and stimulating signals to the liver and pancreas, the company's director of research Jonathan Waataja said.

Once issued, the patent will provide protection until Aug. 4, 2037.

Price: 0.46, Change: +0.15, Percent Change: +48.01